Navigation Links
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
Date:7/30/2008

blood. Amyloid plaques, the pathological hallmark of Alzheimer's disease, are composed largely of aggregated amyloid beta proteins. Amyloid plaques or other types of the amyloid beta protein are thought ultimately to disrupt normal nerve cell function in the brain, leading to the dementia that characterizes Alzheimer's disease.

"We are encouraged that in this study, we saw increased amyloid beta which is thought to be bound to LY2062430, in both the blood and cerebrospinal fluid. We hypothesize that this effect may lead to reduced formation of amyloid plaques in the brain after long-term treatment," said Eric Siemers, M.D., Medical Director, Alzheimer's disease research for Eli Lilly and Company. "Alzheimer's disease is complex, and there's a real need for new treatments that might be shown ultimately to slow disease progression. In addition to the biomarker results, we are particularly encouraged by the finding that patients who received the monoclonal antibody treatment over 12 weeks appeared to have no treatment-related side effects."

In this 12-week Phase II study, researchers gave 52 mild to moderate Alzheimer's disease patients infusions of placebo or LY2062430 in varying doses: 100mg or 400mg once a week, or 100mg or 400mg every four weeks. Alzheimer's disease symptom severity was also evaluated. In addition, 16 volunteers each received a single dose of 100mg of LY2062430 or placebo. For all study participants, safety assessments included magnetic resonance imaging (MRI) and cerebrospinal fluid examinations. A sub-study of 24 patients and 13 volunteers underwent single photon emission tomography (SPECT) scanning using an experimental tracer to assess levels of amyloid beta plaque in the brain.

The interim analysis showed that weekly infusions of LY2062430 up to 400mg per dose was well tolerated, with no side effects related to treatment. An evaluation of MRI brain imaging and an assessment of cerebrospinal fluid showed no evidence of brai
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Ill., Dec. 16 Hospira, Inc. (NYSE: ... medication delivery company, today announced that it will host ... 2009 results and projections for 2010 on Thursday, Feb. ... company will release its fourth-quarter and full-year 2009 results ... and the conference call. ,, A live webcast of ...
(Date:12/16/2009)... International, well-known,scientific experts were ... (80 mg/day),data presented as "extremely promising."[1] ... and clinicians critically reviewed these data.,These ... generic lipid-modifying,treatments, fenofibrate and bezafibrate, in ... in patients with metabolic syndrome,and type ...
(Date:12/16/2009)... -- Verathon®, maker of BladderScan® bladder volume ... bladder volume ultrasound is now included in ... Prevention of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... early November 2009, replace the previous guidelines ... guidelines are located on the Web at: ...
Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 1AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 2AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 3AMICAS Showcases Vendor Neutral Archive Solutions at SIIM 2009 47969 4Mach One Corporation Developing a Nasal Hand Carried Product as Solution to Swine Flu 28H1N1 29 Virus 12476 1Mach One Corporation Developing a Nasal Hand Carried Product as Solution to Swine Flu 28H1N1 29 Virus 12476 2Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 1Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 2Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension 47964 3
... LATHAM, N.Y., Aug. 25 Clinicians from ... Physicians in,Latham have commenced treating cancer patients using ... VAR ), an,advancement that delivers a highly-precise image-guided,intensity-modulated ... RapidArc treatments spare healthy tissue and other ...
... Studies ... Planned, COPENHAGEN, Denmark, ... in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) announced ... and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have worked ...
Other Medicine Technology:Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:12/16/2009)... Gala Raises Significant Funds to Benefit of Children with ... Christine Taylor, Gary Cole and Zachary Levi Join Ben ... LOS ANGELES, Dec. 16 At its 13th ... remarkable individuals. Hasbro President & CEO ... in recognition of his far-reaching philanthropic leadership and ...
(Date:12/16/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that Paul D. Mintz, M.D. has been ... effective January 1, 2010. ,, Dr. Mintz has ... more than 30 years. He is a tenured Professor ... School of Medicine. He also serves as director of ...
(Date:12/16/2009)... ANN ARBOR, Mich., Dec. 16 The most widely ... a finding that raises social justice questions that must ... benefit from stem cell advances, according to a University ... study of its kind, the U-M team analyzed 47 ... commonly used by stem cell researchers. The scientists determined ...
(Date:12/16/2009)... to disease , , WEDNESDAY, Dec. 16 (HealthDay News) ... leprosy have been identified by scientists in Singapore ... than 10,000 DNA samples from leprosy patients and ... the important role that the innate immune response ... leprosy is not common, the discoveries have significant ...
(Date:12/16/2009)... Fla. University of Florida researchers at work on ... first to predict the spread of the disease using ... 21 million calls to determine how often residents of ... composed of two islands off the coast of Tanzania ... recent years. Its government commissioned the study as part ...
Breaking Medicine News(10 mins):Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:Leprosy Genes Identified 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3
... Medical Technologies,Inc. today announced that its fully integrated, ... won,three "Best in KLAS" awards in the annual ... For the third consecutive year, PrimeSuite received the ... for practices having between six and 25,physicians. ...
... Kathleen Henry has joined Sage Software Healthcare, Inc., as ... , Ms. Henry has more than two ... recently, she served as Vice President, Customer Operations Department ... Department for Vodaphone Japan. During her time leading the ...
... disease than whites, report says , , MONDAY, Dec. 15 ... incidence and death rates in the United States, black men ... to die of the disease. , That finding was contained ... , The Colorectal Cancer Facts & Figures 2008-2010 ...
... have shed more light on the mechanism that regulates ... methyl group is attached to DNA, the genetic material ... is essential for normal growth and development in plants ... and irregularities in its process are associated with diseases ...
... Research Science,and Technology Institute (CRSTI), and Medical ... Phase 2 clinical trial for advanced,heart failure, ... in Cardiac Disease" (CUPID Trial) for which ... American Heart Association Scientific,Sessions 2008. The study ...
... rising food costs, many,families are economizing on groceries but one ... 25 cents per 8-ounce glass, on a gallon basis, milk,offers ... in the,supermarket -- proving key vitamins and minerals like calcium ... ensure moms don,t cut milk from,their grocery lists, the National ...
Other Medicine News:Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 2Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 3Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 4Health News:Sage Software Healthcare Appoints Kathleen Henry Senior Vice President, Customer Service 2Health News:Colorectal Cancer Racial Gap Still Growing 2Health News:Work with fungus uncovering keys to DNA methylation 2Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 2Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 3Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 4Health News:Milk is One Beverage Kansas City Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Kansas City Can't Afford to Keep Off the Grocery List 3
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... & Nephew ECTRA II systems permit the ... tunnel ligament endoscopically, allowing access via two ... minimizing endoscopic lens fogging with good air ... visualization and control. ECTRA knives permit the ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Medicine Products: